MolDX: Next-Generation Sequencing for Solid Tumors

This policy permits coverage, at MAC discretion under NCD 90.2 section D, for NGS-based clinical laboratory tests (including LDTs and FDA-cleared/approved tests) when used for solid tumor testing. The policy explicitly excludes hematologic malignancies, circulating tumor DNA (ctDNA) testing, and germline testing in/for patients with cancer; no documentation or frequency limits are specified in the excerpt.

"Coverage is allowed for next-generation sequencing (NGS) clinical laboratory tests—including lab-developed tests (LDTs), FDA-cleared, and FDA-approved tests—used for solid tumor testing as allowabl..."

Sign up to see full coverage criteria, indications, and limitations.